India is the world's largest supplier of generic medicines by volume, exporting to over 200 countries, according to WHO data.
Why the Same Drug — Costs So Much More in One Brand
Two vials of the same molecule, priced very differently. The gap is real, it is explained by how drug markets work, and it does not reflect a difference in what the medicine does.
- Same molecule, different price — The active ingredient in an approved generic is the same compound at the same dose as the original. The price reflects manufacturing history, not a different substance.
- Patent law explains most of the gap — Brand-name drugs cost more partly because one company spent years discovering and proving the drug. Generics can only enter after patent protection ends, and they do not carry that original cost.
- Regulators check equivalence — India's CDSCO does not take a manufacturer's word for it. Generics and biosimilars must demonstrate they perform the same way as the original before they can be sold.
- Price is not a quality signal — A higher price does not mean a better drug. Your oncologist prescribes based on what the evidence supports for your cancer, not on the price of the vial.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed September 2026
The same active molecule can appear in vials priced very differently because brand-name manufacturers recover the cost of years of discovery and trials, while generic makers enter after the patent expires and compete on price. India's regulator CDSCO requires generics and biosimilars to meet strict equivalence standards before approval. A lower price does not indicate lower quality.
How are brand-name, generic, and biosimilar cancer drugs different?
| Innovator (brand-name) | Generic | Biosimilar | |
|---|---|---|---|
| What it is | The original drug, developed by the company that discovered it and proved it works in clinical trials. | A copy of a small-molecule (chemical) drug, made by another manufacturer after the original patent expires. | A near-identical copy of a biological drug — one made from living cells rather than chemical synthesis. |
| Molecule type | Chemical (small molecule) or biological (large molecule), depending on the drug. | Chemical (small molecule) — the same structure as the original. | Biological (large molecule) — matched as closely as the manufacturing process allows. |
| How CDSCO approves it | Full clinical trial evidence proving safety and efficacy, submitted from scratch. | Bioequivalence studies confirming the drug is absorbed at the same rate and amount as the original. | Comparability studies against the original, plus clinical data — a more demanding pathway than for chemical generics. |
| What approval confirms | Safety and efficacy as proven in the original trials. | Same active ingredient, same dose, same absorption. CDSCO treats it as therapeutically equivalent. | Comparable quality, safety, and efficacy to the original, governed by CDSCO and WHO biosimilar guidelines. |
| Typical price position | Highest — reflects the investment in original discovery, trials, and regulatory work. | Lower, often substantially, once multiple manufacturers enter the market. | Lower than the original biological drug, though typically higher than a chemical generic. |
What makes the brand-name version so much more expensive?
When a pharmaceutical company discovers a new drug and proves it safe and effective in clinical trials, the process takes many years and costs enormous amounts. The company recovers those costs through patent-protected sales before any competitor is allowed to enter the market.
Once the patent expires, other manufacturers can apply to make and sell the same molecule. They do not have to repeat the original trials — only prove that their version behaves the same way in the body. Without that original research debt to recover, they can price lower.
More makers entering the market creates further competition, which pushes prices down again. The same molecule at different price points is a normal consequence of a drug moving through its patent cycle — not a sign that anything is different about the medicine itself.
Who chemotherapy is not for
Chemotherapy is not appropriate for everyone with cancer. Several medical situations make it unsuitable or require careful re-evaluation before it can be considered.
- People whose bone marrow function is severely reduced, because chemotherapy further suppresses the cells that produce blood
- People with significant kidney or liver impairment, because these organs clear most chemotherapy drugs from the body, and reduced function leads to dangerous accumulation
- People whose general fitness is very poor, as assessed by the performance status criteria oncologists use
- People who are pregnant, particularly in the first trimester, when the risk to the developing foetus is highest
- People with active, uncontrolled infection
This list is not exhaustive. Eligibility is decided by an oncologist based on the individual case, the specific cancer type, the drug being considered, and the person's overall health.
Does a higher price mean a better-quality drug?
No. The active ingredient in an approved generic is the same molecule at the same dose as the original. CDSCO requires a generic manufacturer to demonstrate bioequivalence — meaning the drug reaches the bloodstream at the same rate and in the same amount — before it can be sold in India.
For biosimilars, the approval process is more demanding because biological medicines are made in living cells and cannot be copied with perfect precision. The regulator requires comparability studies and clinical data. The word 'similar' in biosimilar reflects the nature of biological manufacturing, not a gap in how the medicine works.
Your oncologist prescribes what the evidence supports for your cancer, your stage, and your health profile. The price of the vial is not part of that clinical decision.
What do these terms actually mean?
- Innovator drug
- The original version of a medicine, brought to market by the company that developed it. Also called the originator or reference product. Protected by a patent for a set number of years, during which no other manufacturer can sell the same molecule.
- Generic
- A copy of a small-molecule (chemical) drug made by another manufacturer after the original patent expires. The active ingredient, dose, and route of administration are the same as the original.
- Biosimilar
- A copy of a biological medicine — one derived from living cells rather than chemical synthesis. Because biological molecules are large and complex, an exact copy is not possible; the biosimilar must be proven comparable in quality, safety, and efficacy by the regulator.
- Bioequivalence
- The regulatory test for chemical generics. It confirms that the drug reaches the bloodstream at the same rate and in the same amount as the original, meaning the body cannot distinguish between them.
- Patent
- A time-limited exclusive right granted to the company that developed a drug. While the patent stands, no other manufacturer can sell the same molecule. When it expires, generic and biosimilar makers can apply to enter the market.
- CDSCO
- The Central Drugs Standard Control Organisation — India's national medicines regulator. It approves all drugs sold in India, including generics and biosimilars, and sets the quality and equivalence standards they must meet before reaching pharmacies.
Did you know?
The manufacturing and quality standards that govern these exports — including to regulated markets in Europe and the United States — are the same standards applied to generic and biosimilar medicines dispensed in Indian oncology clinics.
Source: WHO Prequalification Programme; Pharmaceuticals Export Promotion Council of India (Pharmexcil)
Explore 74 more Chemotherapy and Supportive Medicines by Name topics
Generic, Branded & Biosimilar Chemotherapy in India
- Amrit Pharmacy and Subsidised Cancer Drugs
- Biosimilars: Quality, Regulation and Price
- Can You Buy Chemotherapy Drugs Yourself?
- Cold Chain and Drug Storage: Why It Matters
- Counterfeit and Substandard Cancer Drugs
- Generic vs Branded Chemotherapy in India
- How to Check a Chemotherapy Drug Is Approved
- Is Generic Chemotherapy Safe?
- Jan Aushadhi and Government Pharmacy Options
- Patient Assistance Programmes for Cancer Drugs
- Price Control on Cancer Drugs in India
- Questions to Ask About the Drugs You Are Given
- Rituximab Biosimilars in India
- Trastuzumab Biosimilars in India
- Who Chooses the Brand Used for Your Treatment?
- Why the Same Drug Costs Ten Times More
Chemotherapy Drugs by Name
- 5-Fluorouracil (5-FU, Fluracil): What to Expect
- Bleomycin (Bleocip): What to Expect
- Capecitabine (Xeloda, Capegard, Xabine): The Tablet Form
- Carboplatin (Carboplat, Kemocarb): What to Expect
- Chemotherapy Drug Classes Explained
- Chemotherapy Drug Cost by Name
- Chemotherapy Drugs: A Complete Guide by Name
- Cisplatin (Cisplan, Kemoplat): What to Expect
- Cyclophosphamide (Endoxan, Cycloxan): What to Expect
- Cytarabine (Cytosar): What to Expect
- Docetaxel (Taxotere, Docetax, Daxotel): What to Expect
- Doxorubicin (Adrim, Adriamycin): The Red Injection
- Epirubicin: What to Expect
- Etoposide (Etosid, Fytosid): What to Expect
- Gemcitabine (Gemcite, Gemtaz, Oncogem): What to Expect
- Ifosfamide (Holoxan) and Mesna: Why They Go Together
- Irinotecan (Irinotel): What to Expect
- Liposomal Doxorubicin (Lipodox, Caelyx): How It Differs
- Methotrexate (Folitrax): What to Expect
- Mitomycin, Actinomycin and Less Common Agents
- Nab-Paclitaxel (Abraxane, Nabtaxel): How It Differs
- Oxaliplatin (Oxaliplat, Dacotin): What to Expect
- Paclitaxel (Paclitax, Intaxel, Oncotaxel): What to Expect
- Pemetrexed (Alimta, Pemgem, Pemnat): What to Expect
- Reading Your Chemotherapy Chart
- Temozolomide (Temodal, Temoget): The Brain Tumour Tablet
- Vincristine (Cytocristin, Oncovin): What to Expect
- Vinorelbine (Navelbine): What to Expect
- Which Drugs Affect Fertility?
- Which Drugs Affect the Heart, Kidneys or Lungs?
- Which Drugs Cause Hair Loss and Which Do Not?
- Which Drugs Cause Nausea and How Much?
- Which Drugs Cause Neuropathy?
- Why Was This Particular Drug Chosen for Me?
Drug Interactions, TB & Chronic Medicines
HUB — Chemotherapy Drugs by Name
HUB — Generic, Branded and Biosimilar Chemotherapy in India
HUB — Supportive Medicines Used With Chemotherapy
Supportive Medicines by Name
- Acid Blockers (Pantocid, Rantac) During Chemotherapy
- Allopurinol and Tumour Lysis Prevention
- Antibiotics and Antifungals During Chemotherapy
- Aprepitant (Aprecap, Emend) for Delayed Nausea
- Ayurvedic and Herbal Medicines Alongside Chemotherapy
- Cost of Supportive Medicines Across a Course
- Dexamethasone (Dexona) During Chemotherapy
- Emeset and Ondansetron for Chemotherapy Nausea
- Erythropoietin Injections for Low Haemoglobin
- Filgrastim (Grafeel, Neukine) Injections for Low Counts
- Leucovorin: Rescue and Modulation
- Long-Acting Growth Factor (Peg-Grafeel, Neulastim)
- Loperamide (Eldoper) for Chemotherapy Diarrhoea
- Mesna: Protecting the Bladder
- Mouthwashes and Mouth Care Medicines
- Painkillers That Are Safe During Chemotherapy
- Palonosetron and Longer-Acting Anti-Emetics
- The Medicines You Go Home With After Chemotherapy
- Vitamins and Supplements During Chemotherapy
- Why You Must Not Take Paracetamol Before Checking Your Temperature
Frequently asked questions
My doctor prescribed the generic. Does it work the same as the original?
Yes — for chemical generics, that is precisely what CDSCO approval confirms. Before a generic can be sold in India, the manufacturer must prove bioequivalence: that the drug is absorbed at the same rate and amount as the original. The active ingredient is the same molecule at the same dose. The difference is in who made it and when they entered the market, not in the compound itself. If you have any doubt, ask your oncologist to explain what the prescribed version is and why it was chosen for you.
Why does a biosimilar cost more than a chemical generic?
Because biological medicines are far more complex to manufacture than chemical drugs. A chemical molecule can be replicated with high precision; a biological molecule is produced inside living cells, and the manufacturing process directly shapes the final product. Setting up and validating a facility capable of producing a biosimilar requires substantial investment, and the regulatory approval pathway is more demanding than for a chemical generic. Those costs are reflected in the price, even though the biosimilar is still priced lower than the original biological drug.
Can I switch brands in the middle of my treatment?
For most chemical generics, switching between approved versions mid-course is not a clinical concern because bioequivalence is confirmed and the molecule is identical. For biosimilars, the situation is more nuanced — the evidence on switching during treatment is still developing for some medicines, and oncologists may prefer to keep patients on the same version they started with. Do not switch brands without first telling your oncology team. If your pharmacist offers a different version, mention it at your next appointment before accepting the change.
The pharmacist suggested a different brand. What should I do?
Note the name of the version being offered and ask which manufacturer makes it, then tell your oncology team before accepting the change. Your oncologist can confirm whether it is an approved equivalent for your specific situation. This matters most for biosimilars and for drugs where your team is closely monitoring response. For most standard chemical generics it is unlikely to be a concern, but your team is the right person to confirm that for you individually.
If the drug is off-patent, why is the generic still expensive?
Patent expiry removes the original research cost from the price, but manufacturing, quality testing, regulatory compliance, cold-chain storage, and distribution all cost money regardless of who makes the drug. Some genericised molecules remain relatively expensive because few manufacturers have entered the market, which limits competition. Off-patent does not mean cost-free — it means that one category of cost, the original R&D investment, is no longer in the price. As more makers enter over time, prices generally fall further.
How do I know whether what I am receiving is properly approved?
In India, every drug sold legally must be approved by CDSCO and carry a manufacturing licence number on the label. If you are receiving medicines through a hospital or day-care unit, the pharmacy team is responsible for verifying that all drugs are procured through licensed channels. If you are buying from a retail pharmacy, you can ask for the batch number and the manufacturer's name and check CDSCO's online drug database. If anything about the labelling looks unfamiliar or unclear, raise it with your oncology nurse or pharmacist before accepting the medicine.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Chemotherapy Topics
Browse our complete chemotherapy guide — 1133 pages on side effects, medicines, cost, daily life and care in Hyderabad. Tap any topic to read more.